Welcome to our dedicated page for Logicbio Therapeutics news (Ticker: LOGC), a resource for investors and traders seeking the latest updates and insights on Logicbio Therapeutics stock.
ContextLogic Holdings Inc. (LOGC) generates news primarily around its transformation into a business ownership platform, its capital allocation decisions and its regulatory milestones. Investors following LOGC news can track how the company evolves from a former operating business into a publicly traded owner of niche, long-duration businesses with management teams whose incentives are aligned with shareholders.
Recent press releases highlight ContextLogic’s agreement to acquire US Salt Parent Holdings, LLC and its subsidiaries, a fully integrated producer of high-purity evaporated salt products. Coverage of this transaction includes details of the purchase agreement, the structure of the deal, the role of key investors such as Emerald Lake Capital, Abrams Capital and BC Partners Credit, and the planned rights offering to existing shareholders. These items help investors understand how ContextLogic intends to deploy its cash, marketable securities and tax attributes into an operating business.
News updates also include quarterly financial results, where ContextLogic reports its net loss, general and administrative expenses, interest income and cash and marketable securities balances. Management commentary in these releases discusses the company’s focus on operating efficiently while pursuing value maximization through organic growth and accretive acquisitions.
Additional LOGC news items cover corporate reorganization steps designed to protect net operating losses, the voluntary delisting from The Nasdaq Global Market and transition to the OTCQB Venture Market, proxy solicitations related to the reorganization, and changes in key leadership roles. For investors and researchers, the LOGC news feed offers a consolidated view of transaction announcements, financial updates, governance changes and strategic developments. Bookmarking this page allows users to monitor how new acquisitions, board decisions and financing actions shape ContextLogic’s trajectory over time.
Alexion, AstraZeneca Rare Disease, has announced its definitive agreement to acquire LogicBio Therapeutics (NASDAQ: LOGC) for $2.07 per share. This acquisition aims to enhance Alexion's capabilities in genomic medicine by leveraging LogicBio's unique gene delivery and editing technologies, as well as its experienced R&D team. The deal, approved by both boards, is expected to close within four to six weeks, pending shareholder approval. This strategic move underscores Alexion's commitment to advancing treatments for rare genetic diseases.
LogicBio Therapeutics (NASDAQ: LOGC) announced a definitive agreement for its acquisition by AstraZeneca Rare Disease. The agreement involves a cash tender offer of $2.07 per share, approved unanimously by both boards. This acquisition aims to enhance AstraZeneca's capabilities in genomic medicine by integrating LogicBio's technology and experienced R&D team. The deal is projected to close in four to six weeks, pending the tender of at least a majority of shares. Both companies expect to leverage this collaboration to advance treatments for rare genetic diseases.
LogicBio Therapeutics (LOGC) announced promising preclinical results for mLB-001, a gene therapy for methylmalonic acidemia (MMA), published in PLOS ONE. The study demonstrated that a single administration of mLB-001 prevented severe weight loss and mortality in MMUT deficient mice subjected to a high protein diet. This approach shows potential for pediatric patients currently reliant on strict dietary management. The results support the ongoing development of LB-001, aimed at addressing the underlying causes of MMUT deficiency.
LogicBio Therapeutics (LOGC) reported interim data from the SUNRISE trial, showing detectable ALB-2A biomarkers in four pediatric patients indicating gene insertion success. Notably, two patients exhibited increasing ALB-2A levels, suggesting the expansion of edited cells. The proprietary mAAVRx manufacturing process demonstrated a 15-30 fold yield increase compared to standard methods. Financially, LOGC generated $3.2 million in collaboration revenue for Q2 2022, up from $0.8 million in Q2 2021, while net loss decreased to $5.0 million from $10.5 million year-over-year, with cash reserves of $38.8 million.
LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Frederic Chereau will present an overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The pre-recorded presentation will be available for on-demand viewing starting May 24, 2022, at 7:00 a.m. ET. A webcast of the presentation can be accessed on the company's website and will be available for approximately 30 days.
LogicBio focuses on genetic medicine, developing innovative genome editing and gene delivery platforms to address rare diseases.
LogicBio Therapeutics (NASDAQ: LOGC) announced the lifting of the FDA clinical hold on its SUNRISE trial for LB-001, a therapy for pediatric patients with methylmalonic acidemia (MMA). The company plans to resume patient dosing in Q3 2022, with interim clinical data expected by the end of Q2 2022. Financial results for Q1 2022 showed revenue of $2.8 million, an increase from $0.5 million in Q1 2021. R&D expenses decreased to $5.6 million from $6.4 million. The net loss narrowed to $6.7 million, or $0.20 per share, compared to a loss of $10.3 million, or $0.32 per share, in the previous year.
LogicBio Therapeutics (LOGC) announced the presentation of four abstracts at the ASGCT 2022 Annual Meeting from May 16-19, 2022, in Washington D.C. The presentations will cover the preclinical data of GeneRide LB-401, showing significant reduction in disease biomarkers for hereditary tyrosinemia type 1 (HT1). They also highlight advancements in AAV manufacturing, achieving a 15- to 30-fold yield increase and reducing manufacturing timelines from two weeks to four days. These innovations aim to enhance treatment efficacy and reduce manufacturing costs.
LogicBio Therapeutics (Nasdaq: LOGC) has announced that the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia. The FDA's decision follows satisfactory resolutions of previous clinical hold issues, including two cases of thrombotic microangiopathy. The company plans to implement enhanced monitoring measures and resumes dosing by Q3 2022, with interim clinical data expected by the end of Q2 2022.
LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Frederic Chereau will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand starting at 7:00 a.m. ET on March 30, 2022. A webcast of the presentation can be accessed in the Investors section of the company's website, with a replay available for approximately 30 days. LogicBio focuses on genome editing and gene delivery for rare diseases, utilizing its GeneRide™ and sAAVy™ platforms.
LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Frederic Chereau will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET. The discussion will be accessible via a live webcast on the Company's website and will remain available for approximately 30 days post-event. LogicBio focuses on innovative genetic medicine solutions, including its GeneRide™ platform for gene insertion and sAAVy™ for optimized gene delivery, aimed at treating rare diseases across all age groups. For further details, visit their website.
FAQ
What is the current stock price of Logicbio Therapeutics (LOGC)?
What is the market cap of Logicbio Therapeutics (LOGC)?
